How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study

L Morin, JW Wastesson, ML Laroche… - Palliative …, 2019 - journals.sagepub.com
Background: The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim: To describe …

How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study.

L Morin, JW Wastesson, ML Laroche, J Fastbom… - Palliative …, 2019 - europepmc.org
Background The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim To describe the …

How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study

L Morin, JW Wastesson, ML Laroche… - Palliative …, 2019 - pubmed.ncbi.nlm.nih.gov
Background The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim To describe the …

[HTML][HTML] How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study

L Morin, JW Wastesson, ML Laroche, J Fastbom… - Palliative …, 2019 - ncbi.nlm.nih.gov
Background: The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim: To describe …

[PDF][PDF] How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study

L Morin, JW Wastesson, ML Laroche… - Palliative …, 2019 - researchgate.net
Background: The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim: To describe …

How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study

L Morin, JW Wastesson, ML Laroche, J Fastbom… - Palliative …, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> The high burden of disease-
oriented drugs among older adults with limited life expectancy raises important questions …

How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study.

L Morin, JW Wastesson, ML Laroche… - Palliative …, 2019 - search.ebscohost.com
Background: The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim: To describe …

How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study

L Morin, JW Wastesson, ML Laroche… - Palliative Medicine: A …, 2019 - diva-portal.org
Background: The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim: To describe …

How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study.

L Morin, JW Wastesson, ML Laroche, J Fastbom… - Palliative …, 2019 - europepmc.org
Background The high burden of disease-oriented drugs among older adults with limited life
expectancy raises important questions about the potential futility of care. Aim To describe the …